Maximilian Schneider: Detecting Cancer Before Symptoms - The Wholomics Metabolomics Breakthrough
You can listen to this podcast episode on:
Maximilian Schneider is the Co-Founder and CTO of Wholomics, an Austrian-American biotech company using metabolomics and AI to detect cancers at their earliest, most treatable stages. Wholomics’ minimally invasive blood-based test has demonstrated remarkable accuracy in identifying hard-to-detect cancers, including pancreatic cancer, positioning the company at the forefront of the early-detection revolution.
